Asset profile
QLM3003
Small molecule
Evidence outlook · registrational
Atopic Dermatitis: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2027-03.
NCT06058000: The study was randomized, quadruple-blind, placebo-controlled, and enrolled 120 participants, with a clinical disease-activity endpoint (EASI-75). However, no primary endpoint results or statistical comparison are available, so the trial provides well-designed but currently incomplete evidence.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 3 direct rivals (same mechanism and indication), 2 same-class, 60 same-indication; 13 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| QLM3003: this drug | Phase 3 | Small molecule | JAK | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| ZL-82 | Phase 2 | Small molecule | JAK | ||
| Tofacitinib (Xeljanz) | Approved | Small molecule | JAK, JAK1/JAK3 | ||
| Filgotinib (Jyseleca) | Phase 3 | Small molecule | JAK, JAK1 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Crisaborole (Eucrisa) | Approved | Small molecule | PDE4 | ||
| Difamilast (Moizerto / Adquey) | Approved | Small molecule | PDE4 | ||
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | ||
| Lebrikizumab (Ebglyss) | Approved | Monoclonal antibody | IL-13 | ||
| Nemolizumab (Nemluvio) | Approved | Monoclonal antibody | IL-31 receptor A | ||
| Roflumilast (Zoryve) | Approved | Small molecule | PDE4 | ||
| Ruxolitinib | Approved | Small molecule | JAK1/2 | ||
| Tapinarof | Approved | Small molecule | Aryl hydrocarbon receptor, Aryl Hydrocarbon Receptor Agonist | ||
| Tralokinumab (Adbry) | Approved | Monoclonal antibody | IL-13 |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
March 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.